GSK must turn down Unilever’s billions
Jan 21, 2022
3 minutes
Matthew Lynn City columnist
![monweeuk220121_article_014_01_02](https://article-imgs.scribdassets.com/6u71rsq4g9gs77a/images/file9WRES2HB.jpg)
![monweeuk220121_article_014_01_01](https://article-imgs.scribdassets.com/6u71rsq4g9gs77a/images/file12WSET23.jpg)
Now that its hand has been revealed, there is no question that Unilever will do its best to acquire the consumer division of GlaxoSmithKline as it completes its demerger (see page 5). Its £50bn offer may rise to £60bn, £70bn, or more. But the institutional investors that will make the decision should still say no. Sure, it is a lot of money to turn down. Shareholders may well
You’re reading a preview, subscribe to read more.
Start your free 30 days